Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

There is an unmet clinical need for simple, accessible biomarkers to select patients who are more likely to respond to immune checkpoint therapy. Here the authors show that a lower neutrophil-to-lymphocyte ratio is associated with better overall and progressive-free survival, as well as higher rate...

Full description

Bibliographic Details
Main Authors: Cristina Valero, Mark Lee, Douglas Hoen, Kate Weiss, Daniel W. Kelly, Prasad S. Adusumilli, Paul K. Paik, George Plitas, Marc Ladanyi, Michael A. Postow, Charlotte E. Ariyan, Alexander N. Shoushtari, Vinod P. Balachandran, A. Ari Hakimi, Aimee M. Crago, Kara C. Long Roche, J. Joshua Smith, Ian Ganly, Richard J. Wong, Snehal G. Patel, Jatin P. Shah, Nancy Y. Lee, Nadeem Riaz, Jingming Wang, Ahmet Zehir, Michael F. Berger, Timothy A. Chan, Venkatraman E. Seshan, Luc G. T. Morris
Format: Article
Language:English
Published: Nature Portfolio 2021-02-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-021-20935-9

Internet

https://doi.org/10.1038/s41467-021-20935-9

Similar Items